ClinicalTrials.gg
CompletedNCT00242580VERITASUpdated Mar 31, 2016Results posted

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

A Phase 3 interventional study of Verteporfin photodynamic therapy and Pegaptanib in Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-03-31.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing Triamcinolone Acetonide in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Triamcinolone Acetonide · Macular Degeneration.

Enrollment
4th of 10
111 · median 68
Started
2005
with 2 others
Phase 3
4 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
1 of 12
Novartis Pharmaceuticals

Among the 12 studies testing Triamcinolone Acetonide in Macular Degeneration, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2005, is one of 4 in phase 3, and was the 6th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

None of the 12 studies testing Triamcinolone Acetonide in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing Triamcinolone Acetonide in Macular Degeneration as a file.
02

Study summary

To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection.

03

Conditions studied

  • Macular Degeneration
  • Choroidal Neovascularization

Keywords

  • AMD
  • age-related macular degeneration
  • choroidal neovascularization
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age >50
  • all types of untreated subfoveal choroidal neovascularization secondary to AMD
  • lesion size \<5400 microns in greater linear dimension (GLD)

Exclusion criteria

Exclusion Criteria:

  • have a history of prior photodynamic therapy, external beam radiation, subfoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy
  • known allergy to verteporfin, triamcinolone or pegaptanib
  • have received prior treatment with Macugen, or other anti-angiogenic compound or any treatment (e.g. Ruboxistaurin, Lucentis [ranibizumab], Retaane [anecortave acetate], squalamine, siRNA, VEGF-Trap etc.) for neovascular AMD
  • have the presence of fibrosis, hemorrhage, pigment epithelial detachments, tear (tip) of the retinal pigment epithelium or other hypoflourescent lesions obscuring greater than 50% of the CNV lesion
  • have had previous pars plana vitrectomy in the study eye

Other protocol-specified inclusion/exclusion criteria applied.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Verteporfin and Triamcinolone 1 mg

    Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.

    Drug: Verteporfin photodynamic therapy · Drug: Triamcinolone acetonide

  • Experimental
    Verteporfin and Triamcinolone 4 mg

    Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.

    Drug: Verteporfin photodynamic therapy · Drug: Triamcinolone acetonide

  • Active comparator
    Verteporfin and Pegaptanib

    Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.

    Drug: Verteporfin photodynamic therapy · Drug: Pegaptanib

Interventions

  • After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.

    Also known as: Visudyne

  • Pegaptanib sodium 0.3 mg administered by intravitreal injection.

    Also known as: Macugen

  • Triamcinolone acetonide administered by intravitreal injection.

    Also known as: Kenalog-40®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decrease in score indicates worsening of vision. This outcome assessed the percentage of participants who lost less than 15 letters of visual acuity at 12 months as compared with baseline.

    Time frame: Baseline to Month 12

Secondary outcomes

  1. Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 5 or more letters of visual acuity at 12 months compared with baseline.

    Time frame: Baseline to Month 12

  2. Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 10 or more letters of visual acuity at 12 months as compared with baseline.

    Time frame: Baseline to Month 12

  3. Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12

    BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at 12 months as compared with baseline.

    Time frame: Baseline to Month 12

  4. Number of Participants Requiring Verteporfin Treatment Throughout the Study

    Participants received study drug at the Baseline visit and subsequent retreatment at 3 month intervals if leakage was detected on the fluorescein angiogram. The cumulative distribution of the number of treatments is shown per arm.

    Time frame: Baseline to Month 12

  5. Mean Change From Baseline in Total Area of Lesion at 12 Months

    Fluorescein angiography (FA) was used to assess total lesion area. All angiographs were sent to the Central Reading Center (CRC) for analysis.

    Time frame: Baseline to Month 12

07

Results

Posted May 2, 2011
Limitations and caveats
Secondary outcome measures were to be assessed at Month 6 and at 24 months. However, this study was not completed but terminated after all patients completed 12 months. Original safety was COSTART now mapped to SOC MedDRA.

Participant flow

The protocol was amended to limit the sample size from 339 to 100. 111 entered the study and and were part of the 12 mo analysis. The study was subsequently terminated. The patients did not receive study drug during the second year of the study.

Participant flow — Overall Study
MilestoneVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Started324138
Completed222924
Not completed101214
Withdrew: Adverse event302
Withdrew: Unsatisfactory therapeutic effect455
Withdrew: Protocol violation001
Withdrew: Subject withdrew consent225
Withdrew: Lost to follow-up030
Withdrew: Death121

Outcome measures

PrimaryPercentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decrease in score indicates worsening of vision. This outcome assessed the percentage of participants who lost less than 15 letters of visual acuity at 12 months as compared with baseline.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.
Percentage of ParticipantsVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.59.463.471.1
SecondaryPercentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 5 or more letters of visual acuity at 12 months compared with baseline.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12
Percentage of ParticipantsVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 1231.312.228.9
SecondaryPercentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 10 or more letters of visual acuity at 12 months as compared with baseline.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months
Percentage of ParticipantsVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months18.82.423.7
SecondaryPercentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12

BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at 12 months as compared with baseline.

Time frame:
Baseline to Month 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12
Percentage of ParticipantsVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 126.3013.2
SecondaryNumber of Participants Requiring Verteporfin Treatment Throughout the Study

Participants received study drug at the Baseline visit and subsequent retreatment at 3 month intervals if leakage was detected on the fluorescein angiogram. The cumulative distribution of the number of treatments is shown per arm.

Time frame:
Baseline to Month 12
Reported as:
Number · Participants
Number of Participants Requiring Verteporfin Treatment Throughout the Study
ParticipantsVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Participants who received 1 treatment11 ± 012 ± 010 ± 0
Participants who received 2 treatments101519
Participants who received 3 treatments9125
Participants who received 4 treatments224
SecondaryMean Change From Baseline in Total Area of Lesion at 12 Months

Fluorescein angiography (FA) was used to assess total lesion area. All angiographs were sent to the Central Reading Center (CRC) for analysis.

Time frame:
Baseline to Month 12
Reported as:
Mean · mm^2
Mean Change From Baseline in Total Area of Lesion at 12 Months
mm^2Verteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
Baseline6.9178 ± 5.94555.6400 ± 3.71546.3011 ± 5.4794
12 Months6.8959 ± 7.68485.8149 ± 4.64658.6245 ± 7.1242
Change from Baseline-0.0219 ± 7.70260.1749 ± 4.23572.3234 ± 5.9370

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Verteporfin + 1 mg Triamcinolone—11/32 (34.4%)32/32 (100%)
Verteporfin + 4 mg Triamcinolone—9/41 (22%)38/41 (92.7%)
Verteporfin + Pegaptanib—10/38 (26.3%)30/38 (78.9%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
ACCIDENTAL INJURYInjury, poisoning and procedural complications2/321/413/38
GASTROINTESTINAL DISORDERGastrointestinal disorders1/320/412/38
PNEUMONIAInfections and infestations1/322/412/38
CORONARY ARTERY DISORDERCardiac disorders0/322/411/38
CEREBRAL INFARCTNervous system disorders0/322/410/38
ANAPHYLACTOID REACTIONImmune system disorders1/320/410/38
INFECTIONInfections and infestations1/320/410/38
NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/320/410/38
ARTERIAL THROMBOSISVascular disorders1/320/410/38
ARTERIOSCLEROSISVascular disorders1/320/410/38
Most frequent other events
Showing 10 of 58
Most frequent other events
EventVerteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + Pegaptanib
CATARACT (Study eye)Eye disorders8/3210/412/38
HYPERTENSIONVascular disorders7/327/412/38
AMD PROGRESSION (Study eye)Eye disorders6/328/413/38
AMD PROGRESSION (Fellow eye)Eye disorders5/326/417/38
EYE HEMORRHAGE (Study eye)Eye disorders5/327/417/38
ACUTE ELEVATED IOP (Study eye)Eye disorders2/327/410/38
INFECTIONInfections and infestations5/322/410/38
PAINGeneral disorders5/324/413/38
RHINITISInfections and infestations3/326/412/38
ACCIDENTAL INJURYInjury, poisoning and procedural complications0/322/415/38

Baseline characteristics

Age, Continuous
Age, Continuous(years)Verteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + PegaptanibTotal
Mean76 ± 978 ± 881 ± 678 ± 8
Sex: Female, Male
Sex: Female, Male(Participants)Verteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + PegaptanibTotal
Female18252063
Male14161848
Region of Enrollment
Region of Enrollment(participants)Verteporfin + 1 mg TriamcinoloneVerteporfin + 4 mg TriamcinoloneVerteporfin + PegaptanibTotal
United States324138111
08

Study locations

1 site
  • Novartis Investigational Site
    Austin, Texas 78793, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a primary completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2005
First posted
Oct 20, 2005
Start
Sep 2005
Primary completionActual
Jan 2008
Results first posted
May 2, 2011
Last update
Mar 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00242580
Collaborators
QLT Inc.
First posted
Oct 20, 2005
Start date
Sep 2005
Primary completion
Jan 2008
Results posted
May 2, 2011
Last update
Mar 31, 2016

Study contacts

Novartis Pharmaceuticals
study chair · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion